Navigation Links
Cognitive Skills May Shrink With Tamoxifen
Date:2/11/2010

Breast cancer drug still has lifesaving qualities, expert stresses

THURSDAY, Feb. 11 (HealthDay News) -- The breast cancer drug tamoxifen -- used for three decades to treat the disease -- appears to affect cognitive abilities, including some types of memory, a new study has found.

"Our results are important for breast cancer patients because intact cognitive functioning is known to be an important precondition for well-being," said study author Christien Schilder, a doctoral student at the Netherlands Cancer Institute in Amsterdam.

After a year of taking tamoxifen (Nolvadex), women in the study scored lower on tests of verbal memory functioning and other cognitive skills than did women taking another breast cancer drug, exemestane (Aromasin).

Both drugs are considered hormone (or endocrine) therapy. Tamoxifen interferes with the activity of estrogen, which can promote the growth of breast cancer. Exemestane is an aromatase inhibitor, which decreases estrogen production in postmenopausal women.

Endocrine therapy is offered to many women with breast cancer, and "the choice for a specific endocrine agent and therapy sequence is, among others, based on the safety profile," Schilder said. "Therefore, we think that our results justify continuing research into the cognitive effects of endocrine therapy for breast cancer patients."

Schilder's study, funded by Pfizer, which makes Aromasin, was published online Feb. 8 in the Journal of Clinical Oncology.

For the study, the researchers gave neuropsychological evaluations to 299 women, including 179 with breast cancer. Testing was done at the start of the study and again after the women with breast cancer had had a year of hormone therapy -- 80 women taking tamoxifen and 99 taking exemestane.

The researchers found that tamoxifen users had lower scores in verbal memory and executive functioning -- which includes such things as being able to shift attention between two different parts of a task -- than did women without breast cancer. Women taking exemestane had smaller declines in these two areas, considered not statistically significant, compared with the healthy women, Schilder noted.

Those on tamoxifen also fared worse on information-processing speed than the exemestane users, the researchers found.

No substantial differences were found between any of the three groups in terms of visual memory, working memory, verbal fluency, reaction speed and motor speed, according to the study.

Exactly why the tamoxifen users fared worse is not known, Schilder said. "The mechanisms of action of tamoxifen on the brain are hardly known yet," she said, adding that one possibility is that tamoxifen might counteract possible beneficial action of estrogen on the brain.

Dr. Victor G. Vogel, vice president of research for the American Cancer Society, said the results were not surprising. And though the reason women on tamoxifen had more cognitive decline isn't known, he said a logical though unproven explanation is that "it may just not be good for your brain not to have estrogen."

However, Vogel emphasized that it's important to keep the study results in perspective, noting the life-saving benefits of tamoxifen.

According to the U.S. National Cancer Institute, "the benefits of tamoxifen as a treatment for breast cancer are firmly established and far outweigh the potential risks."

Said Vogel: "I'll take a little memory loss to keep my patients alive."

More information

The American Cancer Society has more on tamoxifen.



SOURCES: Christien Schilder, doctoral student, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands; Victor Vogel, M.D., national vice president, research, American Cancer Society, Atlanta; Feb. 8, 2010, Journal of Clinical Oncology, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Drug May Ease Cognitive Effects of Huntingtons
2. Hypertension may predict dementia in older adults with certain cognitive deficits
3. HAPPYneuron Launches the First Online Professional Destination for Clinical Cognitive Training.
4. New compound improves cognitive decline, symptoms of Alzheimers disease in rodents
5. First Global, Virtual Summit on Cognitive Health and Performance Features 200 Sharp Brains
6. Expert Panel Reaches Consensus on Our Ability to Improve Cognitive Health
7. Study finds significantly worse outcomes in cancer patients with cognitive impairment
8. Caffeine doesnt reverse the negative cognitive impact of alcohol, study shows
9. Univalor and Cognitive Sensing Inc. to commercialize 4 University of Montreal discoveries
10. Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform
11. Diet, Cognitive Ability May Play Role in Heart Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... PAINWeekEnd ... at 10 North Broadway Avenue, will be an educational and exciting program providing ... in the management of chronic pain. , Oklahoma is in a healthcare crisis. ...
(Date:3/23/2017)... Austin, TX (PRWEB) , ... March 23, 2017 , ... ... fist-sized organs that pack a punch when it comes to maintaining good health. Every ... every 30 minutes, your kidneys filter every drop of your blood, eliminating waste, regulating ...
(Date:3/23/2017)... , ... March 23, 2017 , ... The TouchPoint Solution, ... the world to manage stress and anxiety. , “Buzzies change the way we ... and co-founder of Buzzies. , Since its launch date in December 2016, The TouchPoint ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ?This conference will prominently feature 150+ Hospital and ... and Director, AMN Healthcare: Susan Salka , 43rd President of the United States ... Big Fight My Life In and Out of the Ring: Sugar Ray Leonard , ...
(Date:3/23/2017)... ... March 23, 2017 , ... It’s that time of year again! Time to ... summer internships , which can be frustrating when they don’t even know how ... Group, a boutique public relations firm outside of Philadelphia, have offered these three tips ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical ... significant unmet medical needs in rare diseases, today announced ... webcast on Monday, April 3 during ENDO 2017, the ... Orlando, Florida , to discuss new data regarding ... TransCon PTH and TransCon CNP). Ascendis is ...
(Date:3/23/2017)... , March 23, 2017  A new ... and accurate identification of individuals who carry ... for a rare yet potentially deadly side effect ... bipolar disorder.  The gene HLA-B*15:02 is ... such as Stevens-Johnson syndrome and toxic epidermal necrolysis ...
(Date:3/23/2017)... , March 23, 2017 ... from the TACTI-mel trial of IMP321 in combination with ... the first (1mg/kg) cohort experiencing a complete response. Recruitment ... cohort is expected to be fully recruited by Q317. ... the AIPAC breast cancer study are expected mid-year (recruitment ...
Breaking Medicine Technology: